ReviewVitamins and hormones2016
αKlotho and Chronic Kidney Disease.
Review in Vitamins and hormones, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Relationship of Soluble Klotho and Early Stage of Diabetic Nephropathy: A Systematic Review and Meta-Analysis.Frontiers in endocrinology · 2022Pooled it
- Effect of essential amino acid кetoanalogues and protein restriction diet on morphogenetic proteins (FGF-23 and Кlotho) in 3b-4 stages chronic кidney disease patients: a randomized pilot study.Clinical and experimental nephrology · 2018Trial
- Specific associations of serum FGF23 and soluble Klotho with different types of left ventricular hypertrophy in hypertensive peritoneal dialysis patients: a cross-sectional study.Frontiers in cardiovascular medicine · 2025Article
- Association of cognitive impairment with the interaction between chronic kidney disease and depression: findings from NHANES 2011-2014.BMC psychiatry · 2024Article
- Klotho exerts protection in chronic kidney disease associated with regulating inflammatory response and lipid metabolism.Cell & bioscience · 2024Article
- Soluble Klotho, a Potential Biomarker of Chronic Kidney Disease-Mineral Bone Disorders Involved in Healthy Ageing: Lights and Shadows.International journal of molecular sciences · 2024Review
- Association between serum soluble α-klotho and bone mineral density (BMD) in middle-aged and older adults in the United States: a population-based cross-sectional study.Aging clinical and experimental research · 2023Article
- Klotho and Fibroblast Growth Factor 23 Are Independent of Vitamin D, and Unlike Vitamin D, Are Not Associated With Graft- and Patient Survival After Kidney Transplantation.Transplantation direct · 2023Article
- Cardiovascular remodeling as a result of fibroblast growth factor-23 (FGF-23)/Klotho imbalance in patients with CKD.International urology and nephrology · 2022Article
- The Role of Alterations in Alpha-Klotho and FGF-23 in Kidney Transplantation and Kidney Donation.Frontiers in medicine · 2022Review
- Histone deacetylase 3 (HDAC3) as an important epigenetic regulator of kidney diseases.Journal of molecular medicine (Berlin, Germany) · 2022Review
- Klotho and Mesenchymal Stem Cells: A Review on Cell and Gene Therapy for Chronic Kidney Disease and Acute Kidney Disease.Pharmaceutics · 2021Review
- Echinacoside protects adenine-induced uremic rats from sciatic nerve damage by up-regulating α-Klotho.Journal of musculoskeletal & neuronal interactions · 2021Article
- Acute Impacts of Different Types of Exercise on Circulating α-Klotho Protein Levels.Frontiers in physiology · 2021Article
- Uremic Toxins, Oxidative Stress, Atherosclerosis in Chronic Kidney Disease, and Kidney Transplantation.Oxidative medicine and cellular longevity · 2021Review
- Klotho in Clinical Nephrology: Diagnostic and Therapeutic Implications.Clinical journal of the American Society of Nephrology : CJASN · 2020Review
- Serum Klotho in Living Kidney Donors and Kidney Transplant Recipients: A Meta-Analysis.Journal of clinical medicine · 2020Article
- Performance of soluble Klotho assays in clinical samples of kidney disease.Clinical kidney journal · 2020Article
- Calcification of coronary arteries and aortic valve and circulating a-klotho levels in patients with chronic kidney disease.Journal of thoracic disease · 2020Article
- Micturition defects and altered bladder function in theAmerican journal of clinical and experimental urology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Alpha-Klotho (αKlotho) protein is encoded by the gene, Klotho, and functions as a coreceptor for endocrine fibroblast growth factor-23. The extracellular domain of αKlotho is cleaved by secretases and released into the circulation where it is called soluble αKlotho. Soluble αKlotho in the circulation starts to decline in chronic kidney disease (CKD) stage 2 and urinary αKlotho in even earlier CKD stage 1. Therefore soluble αKlotho is an early and sensitive marker of decline in kidney function. Preclinical data from numerous animal experiments support αKlotho deficiency as a pathogenic factor for CKD progression and extrarenal CKD complications including cardiac and vascular disease, hyperparathyroidism, and disturbed mineral metabolism. αKlotho deficiency induces cell senescence and renders cells susceptible to apoptosis induced by a variety of cellular insults including oxidative stress. αKlotho deficiency also leads to defective autophagy and angiogenesis and promotes fibrosis in the kidney and heart. Most importantly, prevention of αKlotho decline, upregulation of endogenous αKlotho production, or direct supplementation of soluble αKlotho are all associated with attenuation of renal fibrosis, retardation of CKD progression, improvement of mineral metabolism, amelioration of cardiac function and morphometry, and alleviation of vascular calcification in CKD. Therefore in rodents, αKlotho is not only a diagnostic and prognostic marker for CKD but the enhancement of endogenous or supplement of exogenous αKlotho are promising therapeutic strategies to prevent, retard, and decrease the comorbidity burden of CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.